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Abstract
In addition to the previously characterized viruses BK and JC, three new human polyomaviruses (Pys) have been recently
identified: KIV, WUV, and Merkel Cell Py (MCV). Using an ELISA employing recombinant VP1 capsid proteins, we have
determined the seroprevalence of KIV, WUV, and MCV, along with BKV and JCV, and the monkey viruses SV40 and LPV.
Soluble VP1 proteins were used to assess crossreactivity between viruses. We found the seroprevalence (+/2 1%) in healthy
adult blood donors (1501) was SV40 (9%), BKV (82%), JCV (39%), LPV (15%), KIV (55%), WUV (69%), MCV strain 350 (25%),
and MCV strain 339 (42%). Competition assays detected no sero-crossreactivity between the VP1 proteins of LPV or MCV or
between WUV and KIV. There was considerable sero-crossreactivity between SV40 and BKV, and to a lesser extent, between
SV40 and JCV VP1 proteins. After correcting for crossreactivity, the SV40 seroprevalence was ,2%. The seroprevalence in
children under 21 years of age (n=721) for all Pys was similar to that of the adult population, suggesting that primary
exposure to these viruses likely occurs in childhood.
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Introduction
Polyomaviruses are small, non-enveloped dsDNA viruses that
occupy replicative niches in a variety of vertebrates, and have been
extensively studied as oncogenic agents in experimental systems.
Five human polyomaviruses have now been identified: BKV [1],
JCV [2], KIV [3], WUV [4], and most recently, Merkel Cell
Polyomavirus (MCV) [5]. BKV and JCV were discovered in 1971
[1,2] and are apparently ubiquitous as determined by serology
studies, infecting over 80% of some populations by adulthood.
Primary infections with BKV and JCV are still not well
characterized. Both BKV and JCV persist for life, and their tissue
sanctuaries may include mononuclear blood cells (BKV, JCV) and
cells of the proximal renal tubule (BKV). Reactivation of these
viruses in immunocompromised individuals, results in hemorrhag-
ic cystitis, nephropathy (BKV) and progressive multifocal leuko-
encephalopathy (JCV).
KIV and WUV were isolated from respiratory specimens by
PCR methods, indicating a potential for both disease and
transmission via the respiratory route. They have been detected
in populations from 4 continents, suggesting a global distribution
[6–14]. PCR evidence suggests a low prevalence for both KIV and
WUV genomes in respiratory samples from individuals [15].
Neither KIV nor WUV DNA has been detected in blood or urine,
however, KIV has been detected in fecal specimens [3].
MCV was recently discovered in a Merkel cell carcinoma,
integrated into the host cell genome in a manner suggesting a
possible relationship to oncogenesis [5]. Interestingly, MCV has a
close sequence relationship to the primate Lymphotropic Poly-
omavirus (LPV). LPV was first isolated in 1979 from an African
Green Monkey B-lymphoblastoid cell line [16]. Cellular tropism
for LPV includes continuous lines of B lymphoblasts of both
human and monkey origin [17–19]. Original serologic evidence
suggested that an LPV-like virus infection may occur in humans
and more recent assays using specific VP1 reagents have suggested
that 15–25% of humans are seropositive for LPV VP1-reactive
antibodies [20], indicating that exposure to LPV or a virus
antigenically related to LPV occurs in the human population. The
sequence similarity between LPV and MCV raises the possibility
that the seroepidemiology of LPV may be coincident with that of
MCV. Another primate virus, SV40, also has been detected in
human tissues, but its prevalence and relationship to human
disease is controversial.
Little is known about the primary illness associated with
infection or potential disease associations of the newly discovered
human polyomaviruses. Serologic studies indicate that exposure to
BKV and JCV initially occurs during childhood, however, it is
unknown when exposure occurs for LPV, KIV, WUV and MCV.
In order to study exposure to these viruses in humans, we used
recombinant polyomavirus VP1 capsid proteins expressed in E. coli
in an ELISA assay similar to that described previously for HPV
serotype analysis [21,22]. Our serological results provide data on
the prevalence and age-related timeline for infection with the
recently discovered polyomaviruses, KIV, WUV, and MCV, as
well as for those previously identified: SV40, LPV, BKV, and JCV.
Results
Seroprevalence in an adult population
Sera from 1501 adults over the age of 21 were tested for VP1-
reactive antibodies using recombinant VP1 capsomeres from
SV40, BKV, JCV, LPV, MCV, KIV, and WUV. Seroprevalence
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Although seroprevalence values for both KIV and WUV were
high in our population, infection with these viruses was not always
coincident. We detected differential seroreactivity to 2 different
isolates of MCV: 350 (25%) and 339 (46%). Before assessment of
crossreactivity, we detected a seroprevalence of 9% for SV40 and
82% for BKV. These values are consistent with previous reports
[23,24]. Thirty-nine percent of the population had JCV VP1-
reactive antibodies, and 15% of the population had antibodies
against LPV VP1. The LPV seroprevalence was not coincident
with the MCV seroprevalence for either isolate, and the respective
VP1 proteins did not compete for seroreactivity, as described
below. Our data indicate that there may be an age-related waning
of BKV VP1 specific antibodies, however, our data do not suggest
an age-related waning for any of the other 6 polyomaviruses tested
(Figure 1). We did not detect a difference in seroprevalence with
respect to gender for any of the 7 polyomaviruses tested (Table 1).
Age-specific seroprevalence in a pediatric population
The pediatric population consisted of 721 study subjects under
the age of 21. As shown in Figure 1, seroprevalence values for
these individuals were SV40 (9%), BKV(73%), JCV (21%), LPV
(14%), MCV isolate 350 (23%) and MCV isolate 339 (34%), KIV
(56%) and WUV (54%). Antibodies to all the VP1 antigens tested
were detected in children between 1 and 3 years of age in our
study population (Table 1). These data indicate that exposure to
all 7 polyomaviruses may occur early in childhood.
Antibody crossreactivity determined using competition
with soluble VP1 proteins
Our assay allows testing for possible crossreactivity between
VP1 proteins by preincubation of sera with soluble VP1 proteins
prior to the specific ELISA antigen. No serologic crossreactivity
was detected between the VP1 proteins of LPV and either isolate
of MCV or between the VP1 proteins of KIV and WUV (Figure 2).
Interestingly, there were 164 sera in our population that were
seroreactive to the VP1 protein of MCV isolate 350, but not to
339. Also, 560 samples were seroreactive to isolate 339, but not to
isolate 350. Antibody crossreactivity was observed between the
VP1 proteins of SV40 and BKV. Therefore, competition assays
with soluble BKV and JCV VP1 capsomeres were performed for
all SV40 positive samples to determine the extent of SV40
seroreactivity due to crossreactivity with these other viruses. Two
hundred samples were found to have SV40 VP1-reactive
antibodies, 5 of these samples were not found to have
seroreactivity to the VP1 proteins of either BKV or JCV, while
195 samples exhibited coincident seroprevalences with SV40 and
BKV and/or JCV (Figure 3). Of the 195 coincident samples, 83
(43%) samples were competed using VP1 pentamers from both
BKV and JCV, while 62 (32%) samples were competed using only
BKV VP1 pentamers, and 7 (3%) samples were competed using
only JCV VP1 pentamers (Figure 3). The ELISA reactivity of 43
(22%) of the 195 coincident samples were not competed with VP1
capsomeres of either BKV and/or JCV. Therefore, a total of 48
samples (2% of the study population) exhibited SV40 ‘‘specific’’
antibodies (Figure 3). Of these 48 samples, 16 (33%) were from
individuals less than 21 years of age, 20 (42%) were obtained from
individuals between the ages of 21 and 55 years, and 12 (25%)
were obtained from individuals over the age of 55 years (Table S1).
It was not possible from these de-identified samples to determine if
the latter group had received SV40-contaminated polio vaccine.
Discussion
We have determined the seroprevalence for three recently
identified human polyomaviruses (KIV, WUV, and MCV) and
confirmed the seroprevalence of two previously known human
polyomaviruses (BKV and JCV) and two monkey polyomaviruses
(SV40 and LPV) in a human population, using a VP1 capsomere-
based ELISA. Our study evaluates both large adult (n=1501) and
pediatric populations (n=721) to determine the overall prevalence
and age of first exposure to these viruses. Additionally, our assay
evaluated potential serocrossreactivity occurring between these
viruses.
Previous studies of human Py serology have used a variety of
assays, including hemaglutination inhibition (HI) [25–28] and a
virus-like particle (VLP) ELISA-based assay [20,29–31], which
may not be directly comparable. The hemaglutination inhibition
assay requires either intact virions or VLPs and only evaluates a
subset of antibodies. HI may be less sensitive for determining BKV
and JCV VP1 seroreactivity, as compared to enzyme immunoas-
says [32]. Moreover, not all polyomaviruses exhibit hemaglutina-
tion (e.g., SV40) and HA has not yet been assessed for KIV, WUV
and MCV. A VLP-based ELISA may present conformational
epitopes and increased specificity over HI. However, while the
VLP-based assay may measure only a subset of antibodies, the
capsomere assay has the advantage of measuring all VP1-reactive
antibodies, and the use of a casein-glutathione conjugate sterically
projects the capsomeres from the well surface, allowing their full
exposure to the sera. Nonetheless, seroprevalence determinations
are likely somewhat dependent on specific conditions of the assay.
Our observed seropositivity for both WUV (69%) and KIV
(55%) was high, despite a low reported detection rate in
respiratory tract isolates using PCR [7,12,13,33,34]. The PCR
data likely represent active infection or ongoing co-infection,
rather than overall exposure rates. From the age stratification
data, it appears that primary infection with these viruses occurs
during early childhood, with 35% positive between ages 1–3 for
WU and 32% positive for KIV. There was no cross-reactivity
between WUV and KIV, which may have been expected given
only 65% amino acid identity between their VP1 proteins [4].
We found differential seroreactivity to MCV isolates 350 (25%)
and 339 (42%). However, these are not true viral isolates but
rather PCR amplified sequences, since no infectious virus has yet
been characterized for any of the new human polyomaviruses.
The PCR amplifications may have detected defective genomes or
variants with minor sequence mutations that occurred after viral
integration (specific mutational events have been reported for the
Author Summary
Polyomaviruses occupy a replicative niche in animals from
birds to humans. Two human polyomaviruses, BKV and
JCV, were discovered in 1971 and within the last two years,
three new polyomaviruses have been found in humans: KI
(KIV), WU (WUV), and Merkel Cell (MCV) polyomavirus. MCV
was identified in Merkel Cell carcinomas, a rare skin cancer.
To date, it has not been determined what percentage of
the human population is exposed to KIV, WUV, and MCV,
and when initial exposure to these viruses occurs. We
determined that initial exposure to KIV, WUV, and MCV
occurs in childhood, similar to that for the known human
polyomaviruses BKV and JCV, and that their prevalence is
high. We also found evidence that a monkey virus,
Lymphotropic Polyomavirus (LPV), likely has a serologically
related human counterpart. Another monkey polyoma-
virus, SV40, was found at ,2% prevalence, a level that
does not support its role in human disease.
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anticipated if they affected productive infection). The differential
reactivity in our analysis may therefore have resulted from one
PCR variant having a ‘‘less native’’ conformation of the
recombinant VP1 protein used in the assays (although sufficiently
native to generate VP1 pentamers by electron microscopy) or
mutated in critical amino acids that affect a specific epitope.
Interestingly, there were 164 sera in our population that were
seroreactive to the VP1 protein of MCV isolate 350, but not to
339. Also, 560 samples were seroreactive to isolate 339, but not to
isolate 350, suggesting that both isolates of MCV may circulate in
the human population. It remains to be determined when
authentic, infectious isolates are characterized whether there is
actual strain variation in serology. However, as discussed below for
JCV, strain differences likely will not substantially affect overall
seroprevalence data.
If these are actually different strains of MCV, the differential
prevalence may indicate differential geographic exposure frequen-
cies to these MCV isolates [36,37]. Also, MCV isolate 339 may
contain a sero-dominant MCV VP1 epitope not present in isolate
350. Five amino acid differences occur between the VP1 proteins
of MCV 350 and 339. Based on alignment with the VP1 primary
amino acid sequence of SV40 and the known structure of SV40
VP1, MCV 339 and 350 do not vary with respect to the surface
VP1 exposed variable loop regions thought to comprise the major
antigenic determinants, however differences in amino acids
occurring close to the surface may indirectly affect loop
conformation (Figure S2). Specifically, H288 of MCV 350 is
D288 in isolate 339 (Figure S2). Based on alignment with known
SV40 VP1 structure, this amino acid difference occurs close to the
surface near the HI variable loop. It remains to be determined
whether the difference in seroprevalence between MCV isolates
350 and 339 is maintained in suspect disease populations. Our
data also support previous studies suggesting that the human
population has been exposed to an LPV–like virus, antigenically
similar to the primate LPV VP1 [20,38], and LPV-like sequences
have recently been detected in the white blood cells of
immunocompromised individuals [39]. Although the recently
discovered MCV exhibits a high degree of sequence similarity with
LPV (Figure 4) our competition results indicate that MCV and
LPV are antigenically distinct viruses.
While the seroprevalence of BKV in our study population is
consistent with previous reports [23,24], the JCV seroprevalence
(39%) was somewhat lower [30,31]. There may be several reasons
for this finding: 1) epidemiologic evidence suggests that JCV
exposure may differ geographically [24], 2) JCV VP1- specific
antibodies may not have as high affinity for the JCV VP1 proteins
compared to BKV VP1-specific antibodies, resulting in an overall
decreased sensitivity of the JCV assay, 3) although only the MAD-
11 JCV genotype has been found to be serologically distinct [40],
our assay used only genotype 2B and antibodies other than against
genotype 2B may bind that VP1 protein with lower affinity,
reducing the sensitivity of the assay.
BKV VP1 IgG antibodies previously have been observed to
cross-react with SV40 VP1 [20]. Using recombinant VP1 proteins
to compete potential seroreactivity between BKV and SV40, we
found the seroprevalence of SV40 to be approximately 2%
(Figure 3 and Table S1). In the population of individuals who were
seropositive for SV40 and either BKV and/or JCV (n=195),
SV40 seroreactivity could be competed with VP1 pentamers of
both BKV and JCV in 43% of the coincident population. SV40
seroreactivity could be competed with BKV VP1 capsomeres
alone in 32% of coincident samples, while 3% of coincident
samples could be competed only with JCV VP1 capsomeres. If
there was no specific seroreactivity we did not assign seropositivity
to SV40, since we assume that some antibodies must be specific to
SV40 to indicate infection. Indeed, we identified 48 individuals
with ‘‘specific’’ SV40 antibodies, supporting our assumption that
the SV40 serological response is not restricted only to cross-
reactive antibodies with BKV or JCV. It is interesting to speculate
that BKV infection might confer protection against SV40, an
attribute that may have had a selective advantage at one time.
Although we cannot explain the residual SV40 serology of 2%, it is
possible that a yet unidentified human polyomaviruses may
account for this reactivity.
The external surface variable loop domains of the VP1 proteins
may present the dominant epitopes of these viruses. For example,
comparison of the loop regions of SV40 and BKV reveals a high
degree of similarity. Specifically, the BC loops of SV40 and the BK
strain of BKV share 53% identity, while the DE and HI loops
exhibit 71% and 80% identity, respectively. Comparison of the
loops of LPV and MCV, and those of KIV and WUV, reveals
fewer similarities (Figure 4); LPV and MCV exhibit 21% identity
in the BC loop, and 26% and 20% in their respective DE and HI
loops. KIV and WUV share 33% and 38% respective identity in
the BC and DE loops, and only 20% identity in the HI loop.
These differences may account for the lack of crossreactivity
between these viruses.
Our pediatric population exhibits similar seroprevalence values
compared to the adults, indicating that primary infection with
polyomaviruses occurs in childhood (Figure 2). We found
seropositivity to BKV, WUV, KIV, LPV, and MCV appears in
early childhood whereas that for JCV occurs in pre-adolescence
(Figure 1). Additionally, our data suggest there may be an age-
related waning of BKV VP1 specific antibodies, however, our data
do not indicate an age-related waning for any of the other 6
polyomaviruses assayed (Figure 1). While the adult samples are
likely representative of the demographics in the Denver area, and
reflect healthy individuals within the guidelines for blood
donation, the pediatric samples were obtained from inpatients
and outpatients at The Children’s Hospital Denver and although
exclusion criteria were employed, some individuals may have had
co-morbid or intercurrent illnesses.
Although animal models have suggested that polyomaviruses
could be human tumor viruses [41–44] , no substantive cause-
effect relationships have yet been established. The debate over
SV40 induction of human tumors remains controversial [45], and
our data do not support a permissive human infection with SV40,
such as seen with the other human polyomaviruses. If SV40 infects
humans, it is very limited in scope. Furthermore, if a specific
tumor type is presumed attributable to SV40 infection, serological
validation now would be an essential factor in the analysis. The
discovery of MCV integrated in a specific tumor [5] is a possible
indication of the ability of these viruses to contribute to
tumorigenesis, but perhaps only in a subset of cell types and only
in immunosuppressed individuals. The identification of the human
counterpart to LPV may also reveal a connection to human
cancer. However, given the high seroprevalence of these viruses,
Figure 1. Age-specific seroprevalence detected in a Denver, CO, USA study population (n=2222) for 7 polyomaviruses known to
infect humans. A) SV40 (seroreactivity prior to competition with BKV and JCV VP1 proteins; Figure 3, Table S1); B) BKV; C) JCV; D) LPV; E) KIV; F) WUV;
G) MCV isolate 350; H) MCV isolate 339. Standard error bars are shown.
doi:10.1371/journal.ppat.1000363.g001
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PLoS Pathogens | www.plospathogens.org 5 March 2009 | Volume 5 | Issue 3 | e1000363Figure 2. Seroreactivity to VP1 proteins after competition with soluble heterologous VP1 pentamers. A) SV40 seroreactivity competed
with BKV; B) BKV seroreactivity competed with SV40; C) KIV seroreactivity competed with WUV; D) WUV seroreactivity competed with KIV; E) MCV
isolate 350 seroreactivity competed with MCV isolate 339 and LPV; F) MCV isolate 339 seroreactivity competed with MCV isolate 350 and LPV; and G)
LPV seroreactivity competed with MCV isolates 350 and 339. All capsid proteins were competed with themselves as well as with soluble GST as
controls.
doi:10.1371/journal.ppat.1000363.g002
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PLoS Pathogens | www.plospathogens.org 6 March 2009 | Volume 5 | Issue 3 | e1000363serological support of etiologic connections to specific diseases may
be problematic. Nonetheless, these ubiquitous viruses appear to be
significant human pathogens in immunosuppressed populations.
Materials and Methods
Ethics statement
Plasma samples from healthy adult blood donors were obtained
(May and June, 2007) from Bonfils Blood Center (Denver), and
pediatric plasma samples were obtained from The Children’s
Hospital (Denver) using protocols approved by the Colorado
Multiple Institutional Review Board. Consent from human
participants was not obtained. Samples were de-identified and
analyzed anonymously.
Human plasma samples
To ensure a healthy pediatric population for determination of
baseline exposure, the pediatric population excluded patients who
had received intravenous immunoglobulin in the preceding year
and/or patients who had undergone blood, platelet, or plasma
transfusions within two months of obtaining the sample. Children
less than one year of age were excluded from the analysis because
of possible confounding maternal antibodies.
Expression plasmids for recombinant GST-VP1 fusion
proteins
pGEX4T3 plasmids (GE Healthcare) encoding the VP1 capsid
proteins for SV40, LPV, BKV, JCV, KIV,WUV and MCV isolate
339 were obtained and subsequently used for protein production.
The MCV isolate 350 vp1 gene was synthesized according to the
published sequence (Genbank accession number NC_010277)
(Genscript) and subcloned into the BamHI and XhoI restriction
sites of the pGEX4T3 expression vector (GE Healthcare).
Subcloning was verified through DNA sequencing analysis of
regions flanking the insert using the primers: 59-
GCATGGCCTTTGCAGGGC-39 and 59-CGACACTGGCA-
GAGGCCC-39.
Expression and affinity purification of recombinant VP1
proteins
VP1 proteins from SV40, BKV (BK strain), JCV (genotype 2B),
LPV, KIV, WUV and MCV were expressed in E. coli and purified
using affinity chromatography. Briefly, 400 ml cultures of E. coli
containing the pGEX VP1 expression plasmids were grown at
37uC until OD600=4.0. Cultures were cooled to room temper-
ature and induced with 1.25 mM IPTG. Cells were then grown at
room temperature to an OD600 of 8.0. Cells were lysed using a
French Press. A clarified lysate was chromatographed using a
GSTrap FF affinity column (GE Healthcare) to bind recombinant
GST-VP1 capsomeres. Columns were washed with 3 column
volumes of Superdex buffer (40 mM HEPES, pH 7.4; 200 mM
NaCl; 5% glycerol; 1 mM EDTA, 5 mM DTT, pH 7.2), and
GST-VP1 capsomeres were eluted from the column with 10
column volumes of Superdex buffer supplemented with 10 mM
reduced glutathione. Protein fractions were combined, buffer
exchanged, aliquoted, and stored at 280uC for use in capture
ELISA assays.
Soluble VP1 proteins used in competition assays were purified
as described above. After buffer exchange, GST-VP1 capsomeres
were incubated with glutathione sepharose beads (GE Healthcare)
for 1 hr at 4uC. GST tags were cleaved with 50 U of thrombin in
10 ml lysis buffer (40 mM HEPES, pH 7.4; 200 mM NaCl; 5%
glycerol; 1 mM EDTA), supplemented with 10 mM DTT.
Cleaved VP1 pentamers were collected, concentrated, aliquoted,
and stored at 280uC for use in competition assays.
GST-VP1 capture ELISA
N-terminal GST-tagged pentameric VP1 capsomeres were
captured on polysorp 96-well plates (Nunc) using a casein-
glutathione conjugate [22]. Plasma samples were diluted 1:50 in
block buffer (5% (w/v) evaporated milk powder; 0.05% (v/v)
Tween 20 in phosphate buffered saline, pH 7.4) and incubated
with the immobilized GST-VP1 antigen. IgG antibodies were
detected using an HRP-labeled secondary antibody, and tetra-
methylbenzidine with hydrogen peroxide as a substrate. Positive
control antibodies were: anti-LPV VP1 monoclonal antibody for
LPV VP1 antigen and human sample 637 for both MCV VP1
antigens. We provided BKV VP1 pentamers to Bio-Synthesis Inc,
for production of an anti-BKV polyclonal antibody. At a
concentration of 1:50,000, the BKV polyclonal rabbit sera reacted
with SV40, BKV, JCV, KIV, and WUV VP1 antigens. Negative
controls included capture of GST alone and subsequent
incubation with control antibodies for each antigen. ELISA assays
for 90 samples were repeated for all 8 antigens tested.
Figure 3. SV40 seroreactive samples competed with JCV and
BKV VP1 proteins. 195 samples exhibiting initial SV40 seroreactivity
(Figure 1A) were re-analyzed after pre-incubation with soluble BKV and/
or JCV VP1. The percentages indicate the number of samples for which
SV40 seroreactivity was eliminated by the designated pre-incubation
conditions. No competition was observed for 43/195 (23%) of the
samples.
doi:10.1371/journal.ppat.1000363.g003
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PLoS Pathogens | www.plospathogens.org 7 March 2009 | Volume 5 | Issue 3 | e1000363Figure 4. Genetic variability of VP1 proteins among polyomaviruses. A) phylogenetic analysis of 17 known polyomaviruses [45]: B) Crystal
structure of VP1 monomer derived from pdb id 3BWQ. PyMOL [46] was used to illustrate the surface variable loop regions C) amino acid primary
sequence alignments of VP1 variable loop regions for SV40 and BKV, LPV and MCV, and KIV and WUV.
doi:10.1371/journal.ppat.1000363.g004
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PLoS Pathogens | www.plospathogens.org 8 March 2009 | Volume 5 | Issue 3 | e1000363Reproducibility was assessed based on agreement of seropositivity
for each sample run on different days. Kappa statistics indicated a
high degree of agreement between samples: SV40 (0.8515), LPV
(0.8218), BKV (0.8668), JCV (0.8062), WUV (0.9076), KIV
(0.8851), MCV isolate 350 (0.9446), MCV isolate 339 (0.7976).
Determination of cut-off-values (COVs)
Net absorbance values were calculated by subtracting the mean
absorbance value of the negative control from the mean raw
absorbance value read at 450 nm. COVs were determined by
ranking net absorbance values and determining the inflection
point for each antigen (Figure S1). The COV for the VP1 antigens
of SV40, BKV, JCV, LPV, KIV, and MCV isolate 350 VP1
antigens was 0.2. The COV for the VP1 antigen of MCV isolate
339 was 0.22. The COV for WUV VP1 antigen was 0.25.
Recombinant GST-VP1 capsomere-based competition
assay
To determine sera crossreactivity between two or more VP1
proteins, soluble VP1 proteins were purified and plasma samples
were pre-adsorbed using these proteins to compete potential
crossreactive antibodies in the ELISA assay. Specifically, VP1
capsomere proteins were added to a 1:50 dilution of plasma and
incubated for 1 hr at 4uC prior to incubating samples with
immobilized test antigen. Initially, VP1 capsomeres were titrated
to determine the concentration needed to effectively compete
crossreactive antibodies (Figure 2). From this titration experiment
it was determined that 3.0 mg/ml of competing soluble VP1 was
sufficient for the competition assays. Competition assays for SV40
seroprevalence were performed on those samples that exhibited
coincident seroreactivity for BKV and/or JCV (Figure 3).
Statistical analysis
Seroprevalence values were rounded to the nearest integer. Chi
square and Fischer’s exact tests were performed to determine
whether there was a difference in seroprevalence for any of the
VP1 antigens tested with regard to gender. We stratified the
pediatric and adult population by age, as shown in Table 1.
Significant differences in cumulative seroprevalence among the
age categories were determined by comparing standard errors in
each group (Figure 1). SAS version 9.0 was used for all statistical
analyses performed.
Supporting Information
Figure S1 Determination of inflection points for VP1 antigens
assayed utilizing the VP1-GST ELISA A) SV40 VP1; B) BKV
VP1; C) JCV VP1; D) LPV VP1; E) KIV VP1; F) WUV VP1; G)
MCV VP1 isolate 350; H) MCV VP1 isolate 339.
Found at: doi:10.1371/journal.ppat.1000363.s001 (0.43 MB PDF)
Figure S2 Alignment of primary amino acid sequences for the
VP1 proteins of MCV isolate 350 and MCV isolate 339. Variable
loop regions are highlighted.
Found at: doi:10.1371/journal.ppat.1000363.s002 (0.07 MB PDF)
Table S1 Age distribution of SV40 sero-reactive samples after
competition with heterologous VP1 capsomeres.
Found at: doi:10.1371/journal.ppat.1000363.s003 (0.03 MB PDF)
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